Opinion

Video

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

Author(s):

Axel Merseburger, MD, PhDM. Carmen Mir, MD, PhD

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Related Videos
Video 8 - 2 KOLs featured in , "Q&A: Final Questions on Glioblastoma and Neuroimaging"
Video 7 - 2 KOLs featured in, "Implementing PET RANO 1.0 Response Criteria in Glioblastoma Assessment "
Suneel Kamath, MD
Rohan Garje, MD
Manmeet Ahluwalia, MD, MBA, FASCO
Suneel Kamath, MD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Related Content
Benjamin L. Maughan, MD, PharmD, of Huntsman Cancer Institute
June 11th 2024

Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Benjamin L. Maughan, MD, PharmD
June 7th 2024

Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches

Jack Khouri, MD
November 9th 2023

Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis

Benjamin L. Maughan, MD, PharmD
June 6th 2024

Advancements With Combination Therapies in RCC Usher in New Questions

Brian Rini, MD
June 5th 2024

Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC